Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.
Takeshi Kato(Osaka National Hospital), Hidetoshi Eguchi(Osaka Gakuin University), Mamoru Uemura(Osaka International Cancer Institute), Atsuyo Ikeda(The University of Osaka), Junichi Hasegawa(Osaka Rosai Hospital), Tsunekazu Mizushima(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Taroh Satoh(Osaka University Hospital), Masataka Ikeda(Hyogo Medical University), Yasuhiro Miyake(Nishinomiya Municipal Central Hospital), Hirofumi Ota(Japan Society of Laparoscopic Colorectal Surgery), Chu Matsuda(Osaka International Cancer Institute), Hitoshi Fujii(Mejiro University), Masayoshi Yasui(Osaka International Cancer Institute), Tatsushi Shingai(Kinki Central Hospital)
Cited by 0
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366